Diagnosis & Disease Information

New Oral Therapy Shows Promise Against Neurofibromatosis Type 1-Related Plexiform Neurofibromatomas in Children

Joyce Pagan

January 3, 2017

In this clinical trial, researchers determined the safety and efficacy of selumetinib, a selective MEK inhibitor, in children with NF1-related neurofibromas.

General Oncology

Widely Prescribed Pain and Anti-inflammation Drug Decreased Cancer Growth

Megan Garlapow, PhD

June 17, 2016

A widely prescribed pain/anti-inflammatory medication reduced the growth of neurofibromatosis type 2 tumors in mice and in cell cultures, suggesting that the drug could reduce tumor growth in some cancers.

Next post in General Oncology

Diagnosis & Disease Information

New Oral Therapy Shows Promise Against Neurofibromatosis Type 1-Related Plexiform Neurofibromatomas in Children

Widely Prescribed Pain and Anti-inflammation Drug Decreased Cancer Growth

Surrogate End Points Are Poor Predictors of Survival in Cancer Drug Approval